title: [A primer on the management of antiviral resistance in chronic hepatitis B].
abstract: Treatment options for chronic hepatitis B have significantly expanded over the last decade. Six nucleoside or nucleotide analogs (NA) with activity against the hepatitis B virus are currently available. Prolonged NA treatment is required in many cases to maintain viral suppression, with an inherent risk of the development of antiviral resistance. The purpose of this concise review is to provide an introduction to the prevention, diagnosis and management of antiviral resistance in chronic hepatitis B.
authors.affiliation: Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne. Christopher.Doerig@chuv.ch
authors.forename: C
authors.initials: C
authors.lastname: Doerig
authors.forename: R
authors.initials: R
authors.lastname: Sahli
authors.forename: A
authors.initials: A
authors.lastname: Telenti
authors.forename: D
authors.initials: D
authors.lastname: Moradpour
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents